Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986226 alone or with nivolumab/ipilimumab in advanced solid tumors
NCT03251924Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2017
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label trial of BMS-986226 in solid tumor (advanced stage) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants Experiencing Adverse Events (AEs), Number of Participants Experiencing Serious Adverse Events (SAEs) and 1 more. Started Sep 2017; status: terminated.
02
Drugs
BMS-986226
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03251924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251924.